Skip to Main Content

++

Chapter 96. Chronic Leukemias and Multiple Myeloma

++
++
++

First-line treatment options for newly diagnosed Ph positive chronic phase CML include:

++
++
++

A. Bosutinib, dasatinib, and imatinib

++
++

B. Bosutinib, imatinib, and ponatinib

++
++

C. Dasatinib, imatinib, and nilotinib

++
++

D. Imatinib, ponatinib, and omacetaxine

++
++

E. Imatinib, ibrutinib, and omacetaxine

++
++
++

Bosulif is in the class of drugs known as:

++
++
++

A. Antimetabolites

++
++

B. Immunomodulatory agents

++
++

C. Monoclonal antibodies

++
++

D. Proteasome inhibitors

++
++

E. Tyrosine kinase inhibitors

++
++
++

Patient counseling points for dasatinib include:

++
++
++

A. Avoiding iron preparations

++
++

B. Avoiding proton pump inhibitors

++
++

C. Discussing hand-foot syndrome

++
++

D. Discussing peripheral neuropathy

++
++

E. Taking with food

++
++
++

JH is a 42-year-old man with chronic phase CML who is being treated with imatinib. He fails to achieve a complete cytogenetic response by 12 months. Which is the most appropriate treatment option?

++
++
++

A. Continue imatinib

++
++

B. Switch to dasatinib

++
++

C. Switch to ponatinib

++
++

D. Switch to omacetaxine

++
++

E. Switch to ibrutinib

++
++
++

CP has chronic phase CML and has not achieved a complete hematologic and cytogenetic response on first-line therapy. Mutational analysis shows the T315I mutations. Which is the most appropriate treatment option?

++
++
++

A. Bosutinib

++
++

B. Dasatinib

++
++

C. Ibrutinib

++
++

D. Nilotinib

++
++

E. Ponatinib

++
++
++

The tyrosine kinase inhibitors used in CML inhibit:

++
++
++

A. BCR-ABL

++
++

B. Bruton pathway

++
++

C. Nuclear factor kappa B

++
++

D. Phosphatidylinositol-3

++
++

E. Vascular endothelial growth factor

++
++
++

Ponatinib has been associated with an increase in:

++
++
++

A. Arterial thrombotic events

+...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.